{"id":11353,"date":"2026-09-29T11:27:36","date_gmt":"2026-09-29T03:27:36","guid":{"rendered":"https:\/\/regask.com\/?p=11353"},"modified":"2026-09-29T11:27:36","modified_gmt":"2026-09-29T03:27:36","slug":"ciencias-de-la-vida-en-septiembre-de-2026-tres-senales-de-que-los-reguladores-estan-actuando-conjuntamente","status":"publish","type":"post","link":"https:\/\/regask.com\/es\/life-sciences-in-september-2026-three-signs-regulators-are-moving-together\/","title":{"rendered":"Ciencias de la vida en septiembre de 2026: Tres se\u00f1ales que los reguladores\u2026"},"content":{"rendered":"<p><span class=\"TextRun SCXW255062761 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW255062761 BCX0\">Septiembre de 2026 dej\u00f3 algo claro en el sector de las ciencias de la vida: los reguladores est\u00e1n empezando a moverse al un\u00edsono. Nuestro Radar de Tendencias rastre\u00f3 la actividad en dispositivos, seguridad de medicamentos y productos biol\u00f3gicos, y el mismo patr\u00f3n se repiti\u00f3. Las autoridades de diferentes continentes est\u00e1n <\/span><span class=\"NormalTextRun SCXW255062761 BCX0\">alineaci\u00f3n<\/span><span class=\"NormalTextRun SCXW255062761 BCX0\"> est\u00e1ndares compartidos, reconociendo las decisiones de los dem\u00e1s y llegando a conclusiones similares en <\/span><span class=\"NormalTextRun SCXW255062761 BCX0\">aproximadamente el<\/span><span class=\"NormalTextRun SCXW255062761 BCX0\"> Al mismo tiempo. Este mes analizamos tres tendencias que explican este cambio. Primero, c\u00f3mo las normas sobre dispositivos m\u00e9dicos y diagn\u00f3sticos in vitro se est\u00e1n fusionando discretamente hacia una base com\u00fan. Segundo, por qu\u00e9 la fecha l\u00edmite del 1 de octubre de la FDA para la E2B(R3) y las Buenas Pr\u00e1cticas Cl\u00ednicas (BPC) revisadas de China apuntan a una r\u00e1pida estandarizaci\u00f3n de la farmacovigilancia. Tercero, c\u00f3mo la dependencia regulatoria est\u00e1 abriendo v\u00edas m\u00e1s r\u00e1pidas para que los productos biol\u00f3gicos entren en nuevos mercados. Para los equipos globales, la convergencia ofrece una oportunidad real, pero solo si se sigue el cronograma de cada autoridad.<\/span><\/span><span class=\"EOP Selected SCXW255062761 BCX0\" data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n\t<div id=\"gap-251642159\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-251642159 {\n  padding-top: 20px;\n}\n<\/style>\n\t<\/div>\n\t\n<h3><strong><span class=\"TextRun MacChromeBold SCXW147708193 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW147708193 BCX0\" data-ccp-parastyle=\"heading 2\">El marco normativo global para dispositivos m\u00e9dicos se est\u00e1 fusionando discretamente.<\/span><\/span><span class=\"EOP Selected SCXW147708193 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;134245418&quot;:true,&quot;134245529&quot;:true,&quot;335559738&quot;:299,&quot;335559739&quot;:299}\">\u00a0<\/span><\/strong><\/h3>\n\t<div id=\"gap-1132075730\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1132075730 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n\t<div id=\"gap-313258140\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-313258140 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span data-contrast=\"auto\">Si gestiona registros de dispositivos o diagn\u00f3sticos in vitro en varios mercados, probablemente se haya acostumbrado a la fragmentaci\u00f3n: distintas clasificaciones, diferentes expectativas de fabricaci\u00f3n y diferentes normativas posteriores a la comercializaci\u00f3n en cada jurisdicci\u00f3n. Esta fragmentaci\u00f3n est\u00e1 empezando a desaparecer. Durante septiembre de 2026, nuestro Radar de Tendencias registr\u00f3 m\u00e1s de 50 novedades oficiales sobre dispositivos m\u00e9dicos y diagn\u00f3sticos in vitro (el tema m\u00e1s activo del mes), y lo m\u00e1s llamativo no fue el volumen, sino la direcci\u00f3n. Los organismos reguladores de distintos continentes est\u00e1n avanzando hacia una base com\u00fan.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.federalregister.gov\/documents\/2026\/09\/11\/2026-18612\/medical-devices-cardiovascular-devi%E2%80%A6\"><span data-contrast=\"none\">La FDA de EE. UU.<\/span><\/a><span data-contrast=\"auto\"> Se han finalizado las clasificaciones de una serie de dispositivos novedosos, incluido el software de notificaci\u00f3n cardiovascular basado en aprendizaje autom\u00e1tico, lo que indica la seriedad con la que ahora se toman los productos adaptativos impulsados por IA. China confirm\u00f3 su revisi\u00f3n de clasificaciones para una serie de dispositivos novedosos, incluido el software de notificaci\u00f3n cardiovascular basado en aprendizaje autom\u00e1tico, lo que demuestra la importancia que se le da ahora a los productos adaptativos impulsados por IA. <\/span><a href=\"https:\/\/english.nmpa.gov.cn\/2025-11\/07\/c_1138710.htm\"><span data-contrast=\"none\">Buenas pr\u00e1cticas de fabricaci\u00f3n<\/span><\/a><span data-contrast=\"auto\"> para dispositivos m\u00e9dicos entra en vigor el 1 de noviembre de 2026. Taiw\u00e1n modific\u00f3 su <\/span><a href=\"https:\/\/www.fda.gov.tw\/tc\/newsContent.aspx?cid=3&amp;id=31726\"><span data-contrast=\"none\">reglamentos de retirada de dispositivos<\/span><\/a><span data-contrast=\"auto\">, y el <\/span><a href=\"https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/medical-devices\"><span data-contrast=\"none\">EMA<\/span><\/a><span data-contrast=\"auto\"> Avanz\u00f3 en su programa piloto con panel de expertos sobre dispositivos innovadores. La inteligencia artificial est\u00e1 presente en todo el proceso, mientras las autoridades convergen en la forma de autorizar software que contin\u00faa aprendiendo despu\u00e9s de llegar al mercado.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Para los equipos de regulaci\u00f3n, esta convergencia est\u00e1 dando paso a nuevas perspectivas. Las expectativas que antes diverg\u00edan dr\u00e1sticamente (documentaci\u00f3n t\u00e9cnica, evidencia cl\u00ednica, sistemas de calidad) se est\u00e1n acercando a un nivel com\u00fan. Esto significa que el trabajo realizado para satisfacer a una autoridad exigente se transfiere cada vez m\u00e1s a otras. Sin embargo, la convergencia no es lo mismo que la armonizaci\u00f3n: cada organismo regulador avanza seg\u00fan su propio cronograma, y la fecha l\u00edmite de noviembre para las Buenas Pr\u00e1cticas de Fabricaci\u00f3n (BPF) en China es un recordatorio concreto de que estar &quot;alineados en principio&quot; sigue significando &quot;actuar antes de una fecha espec\u00edfica&quot;. Los equipos que se beneficiar\u00e1n ser\u00e1n aquellos que sigan el cronograma de cada autoridad, en lugar de asumir un cambio global \u00fanico.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<h3><strong><span class=\"TextRun MacChromeBold SCXW77488179 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW77488179 BCX0\" data-ccp-parastyle=\"heading 2\">Dos plazos, una direcci\u00f3n: la farmacovigilancia se est\u00e1 estandarizando r\u00e1pidamente.<\/span><\/span><span class=\"EOP Selected SCXW77488179 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;134245418&quot;:true,&quot;134245529&quot;:true,&quot;335559738&quot;:299,&quot;335559739&quot;:299}\">\u00a0<\/span><\/strong><\/h3>\n\t<div id=\"gap-8130927\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-8130927 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span data-contrast=\"auto\">El 1 de octubre de 2026 es una fecha que vale la pena marcar. Ese es el d\u00eda en que... <\/span><a href=\"https:\/\/www.fda.gov\/vaccines-blood-biologics\/development-approval-process-cber\/electronic-submission-postmarket-safety-reports\"><span data-contrast=\"none\">La FDA de EE. UU.<\/span><\/a><span data-contrast=\"auto\"> cambio obligatorio al <\/span><a href=\"https:\/\/www.fda.gov\/drugs\/fda-adverse-event-monitoring-system-aems\/fda-adverse-event-monitoring-system-aems-electronic-submissions\"><span data-contrast=\"none\">ICH E2B(R3)<\/span><\/a><span data-contrast=\"auto\"> El formato para la presentaci\u00f3n de informes de seguridad posteriores a la comercializaci\u00f3n entra en vigor, no m\u00e1s transici\u00f3n voluntaria, no m\u00e1s formatos heredados. Llega apenas unas semanas despu\u00e9s de la revisi\u00f3n de China, <\/span><a href=\"https:\/\/www.ccfdie.org\/en\/gzdt\/webinfo\/2026\/06\/1784092178460426.htm\"><span data-contrast=\"none\">Buenas pr\u00e1cticas cl\u00ednicas alineadas con las directrices del ICH<\/span><\/a><span data-contrast=\"auto\"> Entraron en vigor el 1 de septiembre. En conjunto, apuntan a una tendencia global constante hacia la adopci\u00f3n de est\u00e1ndares comunes sobre c\u00f3mo se recopilan, formatean e intercambian los datos de seguridad de los medicamentos.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Pero la armonizaci\u00f3n t\u00e9cnica es solo una parte de la historia que nuestro Radar de Tendencias detect\u00f3 este mes. La otra parte es la convergencia cient\u00edfica en las se\u00f1ales de seguridad (las autoridades llegan cada vez m\u00e1s a las mismas conclusiones sobre el etiquetado y los riesgos casi simult\u00e1neamente), en un contexto de un mes inusualmente intenso de retiradas de productos y alertas de seguridad en \u00c1frica subsahariana, Am\u00e9rica Latina y Oriente Medio. La actividad de farmacovigilancia abarc\u00f3 las nueve regiones que monitoreamos, la mayor cobertura geogr\u00e1fica de cualquier tema relacionado con las ciencias de la vida.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Para cualquier persona que gestione una funci\u00f3n de seguridad global, hay dos conclusiones pr\u00e1cticas. La primera, a corto plazo, es operativa: si sus sistemas no est\u00e1n <\/span><a href=\"https:\/\/www.fda.gov\/vaccines-blood-biologics\/development-approval-process-cber\/electronic-submission-postmarket-safety-reports\"><span data-contrast=\"none\">E2B(R3)<\/span><\/a><span data-contrast=\"auto\">\u2014Preparados, la fecha l\u00edmite de la FDA ya lleg\u00f3. A largo plazo, la perspectiva es estrat\u00e9gica: a medida que las autoridades convergen, una se\u00f1al de seguridad que surge en un mercado se convierte en un fuerte indicador de acciones regulatorias en otros. Tratar cada alerta nacional como un evento aislado subestima la interconexi\u00f3n de estas decisiones. La ventaja competitiva reside en interpretar la primera se\u00f1al como una advertencia temprana para el resto de los mercados de su cartera.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<h3><strong><span class=\"TextRun MacChromeBold SCXW193139655 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW193139655 BCX0\" data-ccp-parastyle=\"heading 2\">Reliance est\u00e1 transformando la forma en que los productos biol\u00f3gicos llegan a nuevos mercados.<\/span><\/span><span class=\"EOP Selected SCXW193139655 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;134245418&quot;:true,&quot;134245529&quot;:true,&quot;335559738&quot;:299,&quot;335559739&quot;:299}\">\u00a0<\/span><\/strong><\/h3>\n\t<div id=\"gap-118938944\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-118938944 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span data-contrast=\"auto\">Durante d\u00e9cadas, introducir un producto biol\u00f3gico o una vacuna en un nuevo pa\u00eds implicaba una sola cosa: una revisi\u00f3n regulatoria completa, que en gran medida duplicaba el trabajo ya realizado en otros lugares. Ese modelo est\u00e1 quedando obsoleto, y septiembre de 2026 ofreci\u00f3 un ejemplo paradigm\u00e1tico. <\/span><a href=\"https:\/\/sidof.segob.gob.mx\/notas\/docFuente\/5797710\"><span data-contrast=\"none\">COFEPRIS de M\u00e9xico<\/span><\/a><span data-contrast=\"auto\"> Se cre\u00f3 un procedimiento abreviado de autorizaci\u00f3n de comercializaci\u00f3n que reconoce formalmente las aprobaciones de la ANVISA de Brasil, un ejemplo concreto de dependencia regulatoria, donde una decisi\u00f3n de referencia confiable sustituye a una evaluaci\u00f3n independiente completa.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">No fue un hecho aislado. Nuestro Radar de Tendencias registr\u00f3 casi 20 novedades en el \u00e1mbito de los productos biol\u00f3gicos, las vacunas y las terapias avanzadas este mes, muchas de ellas con especial atenci\u00f3n a los mercados emergentes. <\/span><a href=\"https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/noticias-anvisa\/2026\/anvisa-atualiza-vacina-da-covid-e-lista-de-medicamentos-de-baixo-risco\"><span data-contrast=\"none\">ANVISA<\/span><\/a><span data-contrast=\"auto\"> Singapur actualiz\u00f3 sus propias listas de vacunas contra la COVID-19 y medicamentos de bajo riesgo; Singapur aprob\u00f3 legislaci\u00f3n que consolida <\/span><a href=\"https:\/\/www.hsa.gov.sg\/announcements\"><span data-contrast=\"none\">funciones reguladoras de la salud<\/span><\/a><span data-contrast=\"auto\"> bajo la HSA, simplificando la supervisi\u00f3n; y la <\/span><a href=\"https:\/\/www.federalregister.gov\/documents\/2026\/06\/24\/2026-12622\/demonstrating-substantial-evidence-%E2%80%A6\"><span data-contrast=\"none\">FDA<\/span><\/a><span data-contrast=\"auto\"> Se han revisado las directrices para demostrar la eficacia sustancial de los f\u00e1rmacos y productos biol\u00f3gicos. El denominador com\u00fan es el acceso: las autoridades est\u00e1n creando v\u00edas de aprobaci\u00f3n m\u00e1s r\u00e1pidas y \u00e1giles, en lugar de reinventar el proceso de revisi\u00f3n cada vez.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">La oportunidad para las empresas es real, pero condicionada. Un expediente s\u00f3lido en un mercado de referencia reconocido se ha convertido en un activo valioso que puede ser transferible, acortando considerablemente el tiempo de aprobaci\u00f3n en las jurisdicciones que adoptan marcos regulatorios. La clave est\u00e1 en que cada marco regulatorio tiene su propia lista de autoridades reconocidas, tipos de productos elegibles y normas de documentaci\u00f3n. Saber con precisi\u00f3n qu\u00e9 aprobaciones son v\u00e1lidas y d\u00f3nde, se est\u00e1 convirtiendo en un elemento fundamental de la estrategia de lanzamiento global, y no en una consideraci\u00f3n regulatoria secundaria.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>September 2026 made one thing clear across life sciences: regulators are starting to move in step. Our Trends Radar tracked activity across devices, drug safety and biologics, and the same pattern kept showing up. Authorities on different continents are aligning shared standards, recognizing each other&#8217;s decisions, and reaching similar conclusions at roughly the same time&#8230;.<\/p>","protected":false},"author":46,"featured_media":9717,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-11353","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blogs"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.5 (Yoast SEO v28.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Life Sciences in September 2026: Key Regulatory Changes<\/title>\n<meta name=\"description\" content=\"Explore signs of harmonization in Life Sciences in September 2026 as regulators align standards across continents.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/es\/ciencias-de-la-vida-en-septiembre-de-2026-tres-senales-de-que-los-reguladores-estan-actuando-conjuntamente\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Life Sciences in September 2026: Three Signs Regulators Are Moving Together\" \/>\n<meta property=\"og:description\" content=\"Explore signs of harmonization in Life Sciences in September 2026 as regulators align standards across continents.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/es\/ciencias-de-la-vida-en-septiembre-de-2026-tres-senales-de-que-los-reguladores-estan-actuando-conjuntamente\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-29T03:27:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/mhra-nice-launch-aligned-licensing-hta-process-accelerate-access-medicines-england.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Shaffa Renaningtyas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Shaffa Renaningtyas\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/life-sciences-in-september-2026-three-signs-regulators-are-moving-together\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/life-sciences-in-september-2026-three-signs-regulators-are-moving-together\\\/\"},\"author\":{\"name\":\"Shaffa Renaningtyas\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/6d86c29c9123b2b67a3ea8e259cdb925\"},\"headline\":\"Life Sciences in September 2026: Three Signs Regulators&hellip;\",\"datePublished\":\"2026-09-29T03:27:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/life-sciences-in-september-2026-three-signs-regulators-are-moving-together\\\/\"},\"wordCount\":916,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/life-sciences-in-september-2026-three-signs-regulators-are-moving-together\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/mhra-nice-launch-aligned-licensing-hta-process-accelerate-access-medicines-england.png\",\"articleSection\":[\"Blogs\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/life-sciences-in-september-2026-three-signs-regulators-are-moving-together\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/life-sciences-in-september-2026-three-signs-regulators-are-moving-together\\\/\",\"name\":\"Life Sciences in September 2026: Key Regulatory Changes\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/life-sciences-in-september-2026-three-signs-regulators-are-moving-together\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/life-sciences-in-september-2026-three-signs-regulators-are-moving-together\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/mhra-nice-launch-aligned-licensing-hta-process-accelerate-access-medicines-england.png\",\"datePublished\":\"2026-09-29T03:27:36+00:00\",\"description\":\"Explore signs of harmonization in Life Sciences in September 2026 as regulators align standards across continents.\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/life-sciences-in-september-2026-three-signs-regulators-are-moving-together\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/regask.com\\\/life-sciences-in-september-2026-three-signs-regulators-are-moving-together\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/mhra-nice-launch-aligned-licensing-hta-process-accelerate-access-medicines-england.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/mhra-nice-launch-aligned-licensing-hta-process-accelerate-access-medicines-england.png\",\"width\":800,\"height\":600,\"caption\":\"Mhra Nice Launch Aligned Licensing Hta Process Accelerate Access Medicines England\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"The Regulatory AI Operating System for High-Performing Teams\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\",\"name\":\"RegASK\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"width\":401,\"height\":401,\"caption\":\"RegASK\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/RegASKRegulatoryAffairs\\\/\",\"https:\\\/\\\/x.com\\\/ASKRegASK\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/RegASK\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@RegASK\",\"https:\\\/\\\/www.crunchbase.com\\\/organization\\\/regask\",\"https:\\\/\\\/www.bloomberg.com\\\/profile\\\/company\\\/1691237D:SP\",\"https:\\\/\\\/pitchbook.com\\\/profiles\\\/company\\\/265004-02\",\"https:\\\/\\\/www.cbinsights.com\\\/company\\\/RegASK\",\"https:\\\/\\\/vimeo.com\\\/RegASK\"],\"legalName\":\"RegASK PTE. LTD.\",\"foundingDate\":\"2018\",\"slogan\":\"Empowering Smarter Regulatory Decisions\",\"description\":\"Agentic AI regulatory intelligence and workflow orchestration platform for Life Sciences and Consumer Products. RegASK combines vertical LLMs, multi-agent AI architecture, and a global community of 1,800+ subject matter experts to deliver regulatory horizon scanning, impact analysis, compliance workflow automation, and audit-ready outputs across 160+ countries.\",\"areaServed\":\"Worldwide\",\"founder\":{\"@type\":\"Person\",\"name\":\"Caroline Shleifer\",\"jobTitle\":\"Founder & CEO\"},\"address\":{\"@type\":\"PostalAddress\",\"streetAddress\":\"79 Science Park Drive, #06-01, Cintech IV\",\"addressLocality\":\"Singapore\",\"postalCode\":\"118264\",\"addressCountry\":\"SG\"},\"contactPoint\":{\"@type\":\"ContactPoint\",\"telephone\":\"+65 6817 6290\",\"contactType\":\"customer service\",\"availableLanguage\":[\"English\",\"French\",\"Japanese\",\"Spanish\",\"Chinese\",\"German\"]},\"numberOfEmployees\":{\"@type\":\"QuantitativeValue\",\"minValue\":50,\"maxValue\":100},\"knowsAbout\":[\"Regulatory Intelligence\",\"Regulatory Compliance\",\"Regulatory Affairs\",\"Workflow Orchestration\",\"Life Sciences Regulation\",\"Consumer Products Regulation\",\"AI-Driven Compliance\"],\"hasCertification\":[{\"@type\":\"Certification\",\"name\":\"ISO\\\/IEC 42001:2023\"},{\"@type\":\"Certification\",\"name\":\"ISO\\\/IEC 27001:2022\"},{\"@type\":\"Certification\",\"name\":\"ISO\\\/IEC 27701\"},{\"@type\":\"Certification\",\"name\":\"ISO\\\/IEC 27018:2019\"},{\"@type\":\"Certification\",\"name\":\"SOC 2 Type II\"}]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/6d86c29c9123b2b67a3ea8e259cdb925\",\"name\":\"Shaffa Renaningtyas\",\"sameAs\":[\"https:\\\/\\\/regask.com\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ciencias de la vida en septiembre de 2026: Cambios regulatorios clave","description":"Analizaremos los indicios de armonizaci\u00f3n en las ciencias biol\u00f3gicas en septiembre de 2026, a medida que los organismos reguladores unifiquen las normas en todos los continentes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/es\/ciencias-de-la-vida-en-septiembre-de-2026-tres-senales-de-que-los-reguladores-estan-actuando-conjuntamente\/","og_locale":"es_ES","og_type":"article","og_title":"Life Sciences in September 2026: Three Signs Regulators Are Moving Together","og_description":"Explore signs of harmonization in Life Sciences in September 2026 as regulators align standards across continents.","og_url":"https:\/\/regask.com\/es\/ciencias-de-la-vida-en-septiembre-de-2026-tres-senales-de-que-los-reguladores-estan-actuando-conjuntamente\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2026-09-29T03:27:36+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/mhra-nice-launch-aligned-licensing-hta-process-accelerate-access-medicines-england.png","type":"image\/png"}],"author":"Shaffa Renaningtyas","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Shaffa Renaningtyas","Est. reading time":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/life-sciences-in-september-2026-three-signs-regulators-are-moving-together\/#article","isPartOf":{"@id":"https:\/\/regask.com\/life-sciences-in-september-2026-three-signs-regulators-are-moving-together\/"},"author":{"name":"Shaffa Renaningtyas","@id":"https:\/\/regask.com\/#\/schema\/person\/6d86c29c9123b2b67a3ea8e259cdb925"},"headline":"Life Sciences in September 2026: Three Signs Regulators&hellip;","datePublished":"2026-09-29T03:27:36+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/life-sciences-in-september-2026-three-signs-regulators-are-moving-together\/"},"wordCount":916,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/life-sciences-in-september-2026-three-signs-regulators-are-moving-together\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/mhra-nice-launch-aligned-licensing-hta-process-accelerate-access-medicines-england.png","articleSection":["Blogs"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/regask.com\/life-sciences-in-september-2026-three-signs-regulators-are-moving-together\/","url":"https:\/\/regask.com\/life-sciences-in-september-2026-three-signs-regulators-are-moving-together\/","name":"Ciencias de la vida en septiembre de 2026: Cambios regulatorios clave","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/life-sciences-in-september-2026-three-signs-regulators-are-moving-together\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/life-sciences-in-september-2026-three-signs-regulators-are-moving-together\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/mhra-nice-launch-aligned-licensing-hta-process-accelerate-access-medicines-england.png","datePublished":"2026-09-29T03:27:36+00:00","description":"Analizaremos los indicios de armonizaci\u00f3n en las ciencias biol\u00f3gicas en septiembre de 2026, a medida que los organismos reguladores unifiquen las normas en todos los continentes.","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/life-sciences-in-september-2026-three-signs-regulators-are-moving-together\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/regask.com\/life-sciences-in-september-2026-three-signs-regulators-are-moving-together\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/mhra-nice-launch-aligned-licensing-hta-process-accelerate-access-medicines-england.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/mhra-nice-launch-aligned-licensing-hta-process-accelerate-access-medicines-england.png","width":800,"height":600,"caption":"Mhra Nice Launch Aligned Licensing Hta Process Accelerate Access Medicines England"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"El sistema operativo de IA regulatoria para equipos de alto rendimiento","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/regask.com\/#organization","name":"RegASK","url":"https:\/\/regask.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/","url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","width":401,"height":401,"caption":"RegASK"},"image":{"@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","https:\/\/x.com\/ASKRegASK","https:\/\/www.linkedin.com\/company\/RegASK\/","https:\/\/www.youtube.com\/@RegASK","https:\/\/www.crunchbase.com\/organization\/regask","https:\/\/www.bloomberg.com\/profile\/company\/1691237D:SP","https:\/\/pitchbook.com\/profiles\/company\/265004-02","https:\/\/www.cbinsights.com\/company\/RegASK","https:\/\/vimeo.com\/RegASK"],"legalName":"RegASK PTE. LTD.","foundingDate":"2018","slogan":"Empowering Smarter Regulatory Decisions","description":"Plataforma de inteligencia regulatoria y orquestaci\u00f3n de flujos de trabajo con IA para ciencias de la vida y productos de consumo. RegASK combina modelos de negocio verticales, arquitectura de IA multiagente y una comunidad global de m\u00e1s de 1800 expertos para ofrecer an\u00e1lisis de horizontes regulatorios, an\u00e1lisis de impacto, automatizaci\u00f3n de flujos de trabajo de cumplimiento y resultados listos para auditor\u00edas en m\u00e1s de 160 pa\u00edses.","areaServed":"Worldwide","founder":{"@type":"Person","name":"Caroline Shleifer","jobTitle":"Founder & CEO"},"address":{"@type":"PostalAddress","streetAddress":"79 Science Park Drive, #06-01, Cintech IV","addressLocality":"Singapore","postalCode":"118264","addressCountry":"SG"},"contactPoint":{"@type":"ContactPoint","telephone":"+65 6817 6290","contactType":"customer service","availableLanguage":["English","French","Japanese","Spanish","Chinese","German"]},"numberOfEmployees":{"@type":"QuantitativeValue","minValue":50,"maxValue":100},"knowsAbout":["Regulatory Intelligence","Regulatory Compliance","Regulatory Affairs","Workflow Orchestration","Life Sciences Regulation","Consumer Products Regulation","AI-Driven Compliance"],"hasCertification":[{"@type":"Certification","name":"ISO\/IEC 42001:2023"},{"@type":"Certification","name":"ISO\/IEC 27001:2022"},{"@type":"Certification","name":"ISO\/IEC 27701"},{"@type":"Certification","name":"ISO\/IEC 27018:2019"},{"@type":"Certification","name":"SOC 2 Type II"}]},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/6d86c29c9123b2b67a3ea8e259cdb925","name":"Shaffa Renaningtyas","sameAs":["https:\/\/regask.com\/"]}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts\/11353","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/users\/46"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/comments?post=11353"}],"version-history":[{"count":1,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts\/11353\/revisions"}],"predecessor-version":[{"id":11358,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts\/11353\/revisions\/11358"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/media\/9717"}],"wp:attachment":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/media?parent=11353"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/categories?post=11353"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/tags?post=11353"}],"curies":[{"name":"Gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}